ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,836.22
0.16%
US Tech 100
20,222.40
0.00%
Dow Jones
42,297.12
0.86%
Brent Oil
79.805
-0.59%
Bitcoin
95,668.34
1.23%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Ascendis Pharma AS (ASND)

  7. Ascendis Pharma AS (ASND) News

ASND

Ascendis Pharma AS (ASND)

Ascendis Pharma AS
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ASND
DateTimeSourceHeadlineSymbolCompany
01/12/20255:00PMGlobeNewswire Inc.Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ASNDAscendis Pharma AS
01/06/20258:30AMGlobeNewswire Inc.Ascendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ASNDAscendis Pharma AS
12/30/20244:04PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASNDAscendis Pharma AS
12/19/20248:30AMGlobeNewswire Inc.YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in AdultsNASDAQ:ASNDAscendis Pharma AS
12/17/20246:04AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASNDAscendis Pharma AS
12/16/20248:30AMGlobeNewswire Inc.New InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26NASDAQ:ASNDAscendis Pharma AS
12/12/20244:05PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASNDAscendis Pharma AS
12/12/20244:01PMGlobeNewswire Inc.FDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone DeficiencyNASDAQ:ASNDAscendis Pharma AS
12/11/20244:03PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASNDAscendis Pharma AS
12/10/20245:16PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
12/10/20245:07PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
12/10/20245:02PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
12/10/20244:59PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
12/10/20244:58PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
12/10/20244:55PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
12/03/20244:35PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
11/19/20244:08PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
11/14/20244:19PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASNDAscendis Pharma AS
11/14/20244:01PMGlobeNewswire Inc.Ascendis Pharma Reports Third Quarter 2024 Financial ResultsNASDAQ:ASNDAscendis Pharma AS
11/14/20241:28PMEdgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ASNDAscendis Pharma AS
11/14/20249:31AMEdgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ASNDAscendis Pharma AS
11/13/20244:02PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASNDAscendis Pharma AS
11/07/20244:01PMGlobeNewswire Inc.Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024NASDAQ:ASNDAscendis Pharma AS
11/04/20247:05AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASNDAscendis Pharma AS
11/04/20247:00AMGlobeNewswire Inc.Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular DiseasesNASDAQ:ASNDAscendis Pharma AS
10/09/20244:01PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASNDAscendis Pharma AS
09/30/20248:35AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASNDAscendis Pharma AS
09/30/20248:30AMGlobeNewswire Inc.New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024NASDAQ:ASNDAscendis Pharma AS
09/30/20248:30AMGlobeNewswire Inc.Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone DeficiencyNASDAQ:ASNDAscendis Pharma AS
09/27/20244:59PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASNDAscendis Pharma AS
 Showing the most relevant articles for your search:NASDAQ:ASND

Your Recent History

TSXV
RZE.WT
Razor Energy
BIT
BIE
Bioera
BIT
F34690
Vontobel Financial Produ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads